(MYGN) Myriad Genetics - NASDAQ
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 432m USD | Total Return: -10.6% in 12m
Avg Turnover: 6.61M
Qual. Beats: 0
Rev. Trend: 85.5%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -28.0 is critical
Altman Z'' -5.85 < 1.0 - financial distress zone
Fakeout
Tailwinds
No distinct edge detected
Myriad Genetics, Inc. (MYGN) is a molecular diagnostics and precision medicine firm specializing in genetic testing across oncology, women’s health, and pharmacogenomics. The company utilizes DNA sequencing and RNA expression analysis to provide clinical data for hereditary cancer risks, prenatal screenings, and mental health medication selection. Founded in 1991, its business model relies on intellectual property and strategic research collaborations with institutions such as the Mayo Clinic and M.D. Anderson Cancer Center.
The molecular diagnostics sector is characterized by high research and development costs and a complex reimbursement landscape involving private insurers and government payers. Myriad Genetics maintains a diversified portfolio, including the GeneSight test for psychotropic drug selection and companion diagnostics that help determine patient eligibility for specific targeted therapies. Investors can find additional data and performance metrics for Myriad Genetics on ValueRay.
- GeneSight psychotropic test volume expansion drives mental health segment revenue growth
- Medicare reimbursement rate adjustments impact molecular diagnostic testing profit margins
- Strategic shift toward oncology precision medicine increases high-value diagnostic market share
- Operational efficiency initiatives and lab consolidation reduce long-term structural cost basis
- Regulatory scrutiny of laboratory developed tests creates potential compliance and litigation risks
| Net Income: -399.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA 0.47 > 1.0 |
| NWC/Revenue: 22.03% < 20% (prev 16.37%; Δ 5.65% < -1%) |
| CFO/TA 0.00 > 3% & CFO 2.40m > Net Income -399.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (93.7m) vs 12m ago 2.52% < -2% |
| Gross Margin: 69.96% > 18% (prev 70.01%; Δ -0.05% > 0.5%) |
| Asset Turnover: 98.70% > 50% (prev 82.63%; Δ 16.08% > 0%) |
| Interest Coverage Ratio: -27.97 > 6 (EBIT TTM -386.0m / Interest Expense TTM 13.8m) |
| A: 0.27 (Total Current Assets 312.8m - Total Current Liabilities 130.2m) / Total Assets 673.7m |
| B: -1.72 (Retained Earnings -1.16b / Total Assets 673.7m) |
| C: -0.46 (EBIT TTM -386.0m / Avg Total Assets 839.9m) |
| D: 1.00 (Book Value of Equity 337.4m / Total Liabilities 336.3m) |
| Altman-Z'' = -5.85 = D |
| DSRI: 1.03 (Receivables 123.8m/120.4m, Revenue 829.0m/831.3m) |
| GMI: 1.00 (GM 70.01% / 69.96%) |
| AQI: 0.54 (AQ_t 0.29 / AQ_t-1 0.55) |
| SGI: 1.00 (Revenue 829.0m / 831.3m) |
| TATA: -0.60 (NI -399.9m - CFO 2.40m) / TA 673.7m) |
| Beneish M = -3.34 (Cap -4..+1) = AA |
As of June 12, 2026, the stock is trading at USD 4.63 with a total of 1,711,862 shares traded.
Over the past week, the price has changed by -1.28%,
over one month by +9.98%,
over three months by -8.50% and
over the past year by -10.62%.
Myriad Genetics has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold MYGN.
- StrongBuy: 3
- Buy: 3
- Hold: 6
- Sell: 2
- StrongSell: 1
| Analysts Target Price | 6.3 | 35% |
P/E Forward = 46.0829
P/S = 0.7749
P/B = 1.2807
P/EG = 1.2358
Revenue TTM = 829.0m USD
EBIT TTM = -386.0m USD
EBITDA TTM = -334.2m USD
Long Term Debt = 120.3m USD (from longTermDebt, last quarter)
Short Term Debt = 7.10m USD (from shortTermDebt, last quarter)
Debt = 302.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 91.2m
Net Debt = 178.3m USD (calculated: Debt 302.7m - CCE 124.4m)
Enterprise Value = 609.9m USD (431.6m + Debt 302.7m - CCE 124.4m)
Interest Coverage Ratio = -27.97 (Ebit TTM -386.0m / Interest Expense TTM 13.8m)
EV/FCF = -29.32x (Enterprise Value 609.9m / FCF TTM -20.8m)
FCF Yield = -3.41% (FCF TTM -20.8m / Enterprise Value 609.9m)
FCF Margin = -2.51% (FCF TTM -20.8m / Revenue TTM 829.0m)
Net Margin = -48.24% (Net Income TTM -399.9m / Revenue TTM 829.0m)
Gross Margin = 69.96% ((Revenue TTM 829.0m - Cost of Revenue TTM 249.0m) / Revenue TTM)
Gross Margin QoQ = 68.66% (prev 69.97%)
Tobins Q-Ratio = 0.91 (Enterprise Value 609.9m / Total Assets 673.7m)
Interest Expense / Debt = 4.56% (Interest Expense 13.8m / Debt 302.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -304.9m (EBIT -386.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.40 (Total Current Assets 312.8m / Total Current Liabilities 130.2m)
Debt / Equity = 0.90 (Debt 302.7m / totalStockholderEquity, last quarter 337.4m)
Debt / EBITDA = -0.53 (negative EBITDA) (Net Debt 178.3m / EBITDA -334.2m)
Debt / FCF = -8.57 (negative FCF - burning cash) (Net Debt 178.3m / FCF TTM -20.8m)
Total Stockholder Equity = 366.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -47.61% (Net Income -399.9m / Total Assets 673.7m)
RoE = -109.1% (Net Income TTM -399.9m / Total Stockholder Equity 366.6m)
RoCE = -79.28% (EBIT -386.0m / Capital Employed (Equity 366.6m + L.T.Debt 120.3m))
RoIC = -59.89% (negative operating profit) (NOPAT -304.9m / Invested Capital 509.2m)
WACC = 6.43% (E(431.6m)/V(734.3m) * Re(8.41%) + D(302.7m)/V(734.3m) * Rd(4.56%) * (1-Tc(0.21)))
Discount Rate = 8.41% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 3.83%
[DCF] Fair Price = unknown (Cash Flow -20.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.37 | # QB: 0
Revenue Correlation: 85.51 | Revenue CAGR: 5.83% | SUE: -0.40 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.06 | Chg30d=N/A | Revisions=-45% | Analysts=9
EPS next Quarter (2026-09-30): EPS=0.07 | Chg30d=+77.31% | Revisions=+64% | Analysts=9
EPS current Year (2026-12-31): EPS=0.05 | Chg30d=+1.49% | Revisions=+9% | GrowthEPS=-20.4% | GrowthRev=+4.7%
EPS next Year (2027-12-31): EPS=0.15 | Chg30d=-3.08% | Revisions=-23% | GrowthEPS=+216.3% | GrowthRev=+6.0%
[Analyst] Revisions Ratio: +64%